Broad Institute Launches Food Allergy Initiative
News Jun 24, 2016
Researchers from the Broad Institute of MIT and Harvard, its partner institutions, and Yale School of Medicine are launching an initiative to tackle the science of food allergies, a growing public health threat that affects the lives of hundreds of millions worldwide. The Food Allergy Science Initiative (FASI), which will be centered at the Broad, will tap the combined resources of participating academic and research institutions to help answer key scientific questions surrounding food allergies, the causes of which remain little-understood.
“We are bringing together scientists from several disciplines to tackle head on the underlying biology of food allergy,” says Ruslan Medzhitov, who will lead the initiative. Medzhitov is the David W. Wallace Professor of Immunobiology at Yale School of Medicine and an investigator at Howard Hughes Medical Institute. “We believe that the combined scale of our approach will help to transform this field and open up new avenues for treatment and prevention.”
Eight percent of American children suffer from debilitating food allergies, and much remains unknown about the root causes of the condition. Genetics, gut microbes, the immune system, and food-derived allergens—and the interactions between these factors—somehow lead to the breakdown in tolerance that drives food allergy, but we understand little about what leads to food allergy, how to prevent it, and how to resolve it once it arises.
However, with the dramatic advances in genomic technologies, immunology, and microbiome research in the past decade, scientists are now in a unique position to explore the biological mechanisms behind food allergies. Among the cutting-edge technologies the Broad will bring to bear on food allergy research are single-cell genomic analysis—which will reveal new information about the cell populations involved in the allergic response—and CRISPR genome-editing techniques, which will enable large-scale screens to test the role individual genes play in food allergy.
“There has been an urgent call for answers within the food allergy advocacy community, and a lot of great work is already underway,” says Aviv Regev, a core institute member of the Broad, a Howard Hughes Medical Institute investigator, and part of FASI’s scientific leadership. “However, we know too little about the basic biological mechanisms that underlie these allergies. We believe that with an ambitious, interdisciplinary approach, and a partnership between immunologists, clinicians, technologists, and computational scientists we can help speed research and enhance scientific understanding of food allergy in a manner that would translate in the future to improved diagnostics and therapies.”
The newly-founded initiative currently involve researchers from Yale School of Medicine, Brigham and Women’s Hospital (BWH), Harvard Medical School (HMS), Massachusetts General Hospital (MGH), and MIT, in addition to the Broad. Along with Medzhitov and Regev, FASI’s scientific leadership includes Vijay Kuchroo (Broad, HMS, BWH); J. Christopher Love (Broad, MIT); Wayne Shreffler (MGH, HMS); and Ramnik Xavier (Broad, MGH, MIT, HMS).
They enter a near-barren landscape in terms of our understanding of the fundamental biological mechanisms underlying food allergy. Currently, diagnosing and treating food allergy is a major challenge: allergic reactions, which can be life-threatening, are the primary means of diagnosis, and treatment is limited to avoidance of known allergy-causing foods and epinephrine injections, which are only administered once an allergic reaction has been triggered. Understanding the basic biology that drives the allergic response to food is a first step needed to catalyze research.
FASI aims to accelerate the pace of discovery in this field and enable the development of new diagnostics and treatments through a coordinated effort that brings together specialists from a variety of disciplines including immunology, gastroenterology, computational biology, molecular biology, and bioengineering to answer fundamental questions pertaining to food allergy.
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE